Clinical Trials on Lung Cancer (NSCLC)

Total 96191 results

Washington University School of Medicine
Boston Scientific Corporation

Completed

EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Single Scope Staging of Lung Cancer With Endosonography (SCORE)

Non Small Cell Lung Cancer (NSCLC) | Indication Mediastinal Staging | Complete Endosonography

Netherlands, Belgium
Eucure (Beijing) Biopharma Co., Ltd

Withdrawn

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)

HCC | NSCLC Stage IV | NSCLC Stage IIIB

China, Australia, Taiwan, Armenia, Austria
Samsung Medical Center
CytoGen, Inc.; UNIST (Ulsan National Institute of Science and Technology)

Active, not recruiting

Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor

NSCLC Stage IV | NSCLC Stage IIIB

Korea, Republic of
Hi-Q Marine Biotech International, Ltd.

Withdrawn

To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

NSCLC Stage IV | NSCLC, Stage III

Taiwan
Alethia Biotherapeutics

Completed

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

NSCLC Stage IV

United States, Canada
Ivy Life Sciences, Co., Ltd

Completed

Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer

Lung Cancer | Liver Cancer | NSCLC Stage IV | Hepatocellular Carcinoma by BCLC Stage | NSCLC Stage IIIB
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Duke University
Regeneron Pharmaceuticals

Recruiting

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Non-small Cell Lung Cancer (NSCLC)

United States
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
BeiGene

Terminated

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

China, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
State University of New York - Upstate Medical...

Completed

Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)

Non-small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, Germany, France
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada
Ludwig Institute for Cancer Research
Xcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...

Completed

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Carcinoma | NSCLC | Non-small Cell Lung Cancer

United States
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

Osimertinib Study in Indian Patients

Non Small Cell Lung Cancer (NSCLC)

India
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
UNC Lineberger Comprehensive Cancer Center
Celgene

Completed

Single Arm on the Tolerability of Weekly Nab-paclitaxel

Non Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (KINDLE)

Non-small-cell Lung Cancer (NSCLC)

Mexico, Peru, Argentina, Taiwan, India, Thailand, Colombia, Uruguay, Chile, Dominican Republic
PharmaMar

Completed

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Non-Small Cell Lung Cancer (NSCLC)

United States
Dartmouth-Hitchcock Medical Center
Sanofi; Genentech, Inc.

Completed

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | NSCLC | Non-small Cell Lung Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Pfizer

Completed

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (ARCHER 1042)

Non Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
Peregrine Pharmaceuticals

Completed

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Non Small Cell Lung Cancer (NSCLC)

United States
National Taiwan University Hospital

Completed

Selumetinib in Combination With Gefitinib in NSCLC Patients

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Astex Pharmaceuticals, Inc.

Completed

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Non-small Cell Lung Cancer(NSCLC)

United States, Korea, Republic of, Spain, France, Canada
Grupo de Investigación y Divulgación Oncológica

Unknown

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer (NSCLC)

Spain
Stanford University
Eli Lilly and Company; Genentech, Inc.

Completed

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Yonsei University

Withdrawn

An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NSCLC (Non-Small Cell Lung Cancer)
Yonsei University

Completed

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer (DATE)

Non Small Cell Lung Cancer (NSCLC)

Korea, Republic of
Groupe Francais De Pneumo-Cancerologie

Completed

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) (EGFR-RETRO)

NSCLC Non Small Cells Lung Cancer

France
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
National Health Research Institutes, Taiwan

Terminated

A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

Head and Neck Cancer | NSCLC

Taiwan
University of Miami

Terminated

Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC

United States
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced, NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer

India
Cancer Trials Ireland
University College Dublin; Technological University Dublin

Recruiting

'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) (SOURCE Lung)

NSCLC/Oligometastatic Cancer (Single Lung Lesion)

Ireland
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
SystImmune Inc.

Recruiting

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Lung Cancer | Non Small Cell Lung Cancer

United States
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, Spain, Austria, Japan, Switzerland, Sweden, France, United Kingdom, Hong Kong, Thailand, Turkey, Argentina, Belgium, Greece, Italy, Poland, Portugal, Romania, Latvia, ... and more
Takeda

Recruiting

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY (ENTIRETY)

Non-small Cell Lung Cancer (NSCLC)

Poland
Takeda

Recruiting

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Cancer Research UK
Vaccitech (UK) Limited

Recruiting

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland

Clinical Trials on Lung Cancer (NSCLC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations